Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy

Imagem de Miniatura
Arquivos
art_WEISSMANN_Hepatitis_B_viremia_in_HIVcoinfected_individuals_under_antiretroviral_2019.PDF (681.13 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
FERREIRA, Paulo Roberto Abrao
VIANA, Monica Salum Valverde Borsoi
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.23, n.6, p.441-450, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Antiretroviral therapy (ART) has decreased AIDS incidence and mortality, rendering comorbidities, such as hepatitis B more relevant for people living with human immunodeficiency virus (HIV). Since antiretroviral drugs may also inhibit hepatitis B virus (HBV) replication, analyzing the impact of ART on management of hepatitis B in this population is important. Objective: To assess HBV viremia among HIV/HBV coinfected individuals on ART and its associated factors. Method: For this cross-sectional study, HIV/HBV-coinfected individuals, aged over 18 years, who were on ART for over six months and receiving care at an outpatient clinic in Sao Paulo were recruited. Sociodemographic characteristics, information about viral exposure, clinical and laboratory data, including evaluation of liver fibrosis were obtained. Plasma HBV DNA was measured by polymerase chain reaction. Viral genome sequencing was conducted for genotyping and identification of drug resistance-conferring mutations if viral load exceeded 900 IU/mL. Results: Out of 2,946 patients who attended the clinic in 2015, 83 were eligible and 56 evaluated. Plasma HBV DNA was detected in 16 (28.6%) (95% CI: 18.0-41.3%), all on lamivudine and tenofovir treatment. HBV DNA detection was associated with lower education (p = 0.015), higher international normalized ratios (p = 0.045), history of an AIDS-defining illness [OR: 3.43 (95% CI: 1.10-11.50)], and HBeAg detection [OR: 6.60 (95% CI: 1.84-23.6)]. In contrast, a last CD4+ count above 500 cells/mm(3) in the year prior to inclusion [OR: 0.18 (95% CI: 0.04-0.71)] and detection of anti-HBe [OR: 0.21 (95% CI: 0.04-0.99)] were negatively associated. Patients with HBV DNA above 900 IU/mL were infected with subgenotypes A1 (n = 3) and D2 (n = 1), and exhibited viral mutations associated with total resistance to lamivudine and partial resistance to entecavir. Conclusions: Despite being on ART, a significant proportion of HIV/HBV-coinfected individuals present HBV viremia. Characterization of factors that are associated with this finding may help professionals provide better management to these patients. (C) 2019 Sociedade Brasileira de Infectologia.
Palavras-chave
HIV infections, Hepatitis B, Coinfection, Antiretroviral agents, Viremia, DNA, viral
URI
https://observatorio.fm.usp.br/handle/OPI/34432
Referências
  1. Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
  2. [Anonymous], ABB REALTIME HBV
  3. Babor T, 2001, AUDIT ALCOHOL USE DI
  4. Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
  5. Boyd A, 2014, HEPATOLOGY, V60, P497, DOI 10.1002/hep.27182
  6. Braga PE, 2007, CAD SAUDE PUBLICA, V23, P2653, DOI 10.1590/S0102-311X2007001100013
  7. Brasil. Ministerio da Sande, B EP 2018 HEP VIR
  8. Brasil. Ministerio da Sande, 2003, PROGR NAC DST AIDS C
  9. Brasil. Ministerio da Sande, 2018, PROT CLIN DIR TER MA
  10. da Silva AC, 2010, MEM I OSWALDO CRUZ, V105, P770, DOI 10.1590/S0074-02762010000600007
  11. de Carvalho CV, 2007, REV SOC BRAS MED TRO, V40, P555, DOI 10.1590/S0037-86822007000500013
  12. de Vries-Sluijs TEMS, 2010, GASTROENTEROLOGY, V139, P1934, DOI 10.1053/j.gastro.2010.08.045
  13. European AIDS Clinical Society, VERS 9 0
  14. European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
  15. Gomes-Gouvea MS, 2015, ANTIVIR THER, V20, P387, DOI 10.3851/IMP2938
  16. Gutierrez EB, 2012, AIDS BEHAV, V16, P1482, DOI 10.1007/s10461-012-0168-3
  17. Huang YS, 2019, HEPATOL INT, V13, P431, DOI 10.1007/s12072-019-09953-4
  18. Jang JW, 2015, HEPATOLOGY, V61, P1809, DOI 10.1002/hep.27723
  19. Konopnicki D, 2005, AIDS, V19, P593, DOI 10.1097/01.aids.0000163936.99401.fe
  20. Landrum ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008687
  21. Lieveld FI, 2013, ANN HEPATOL, V12, P380, DOI 10.1016/S1665-2681(19)31000-2
  22. Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1
  23. Matthews GV, 2013, CLIN INFECT DIS, V56, pE87, DOI 10.1093/cid/cit002
  24. Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
  25. Mendes-Correa MC, 2010, J MED VIROL, V82, P1481, DOI 10.1002/jmv.21845
  26. Mendes-Correa MC, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-247
  27. Mendes-Correa Maria Cassia J., 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P81, DOI 10.1590/S0036-46652000000200004
  28. Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG AD AD
  29. Park ES, 2019, J HEPATOL, V70, P1093, DOI 10.1016/j.jhep.2019.02.006
  30. Price H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068152
  31. Rhee SY, 2010, ANTIVIR RES, V88, P269, DOI 10.1016/j.antiviral.2010.09.012
  32. Soriano V, 2010, J ANTIMICROB CHEMOTH, V65, P548, DOI 10.1093/jac/dkp479
  33. Sun HY, 2014, WORLD J GASTROENTERO, V20, P14598, DOI 10.3748/wjg.v20.i40.14598
  34. Tavares N, 2016, REV SAUDE PUBL, P50, DOI [10.1590/51518-8787.2016050006150, DOI 10.1590/51518-8787.2016050006150]
  35. Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800
  36. Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
  37. Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/49
Carregar mais